Welcome to our dedicated page for OCULAR THERAPEUTIX SEC filings (Ticker: OCUL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on OCULAR THERAPEUTIX's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into OCULAR THERAPEUTIX's regulatory disclosures and financial reporting.
Ocular Therapeutix interim CFO Jason Shand Robins reported receiving a stock option grant linked to common shares of the company. On January 20, 2026, he was awarded a stock option to buy 33,000 shares of Ocular Therapeutix common stock at an exercise price of $11.45 per share. The filing shows he beneficially owns 33,000 derivative securities directly after this grant. The option vests over four years, with 1/48 of the underlying shares vesting monthly beginning one month after the grant date, conditioned on his continued service to the corporation.
Ocular Therapeutix, Inc. filed an initial ownership report for interim CFO Jason Shand Robins, detailing his equity holdings in the company as of January 20, 2026. He directly holds 52,656 shares of common stock, which include 20,917 unvested RSUs from a January 13, 2025 grant and 22,425 unvested RSUs from a January 2, 2026 grant. Each RSU represents one share of common stock and is scheduled to vest over three years, with one-third vesting on the first anniversary of the grant date and the remaining two-thirds vesting in equal yearly installments.
Robins also holds two stock option awards: one covering 110,600 shares of common stock at an exercise price of $8.12 per share, expiring on January 12, 2035, and another covering 68,195 shares at $11.82 per share, expiring on January 1, 2036. The first option, granted on January 13, 2025, vests over four years with 25% vesting on January 13, 2026 and the balance vesting monthly over the following three years. The second option, granted on January 2, 2026, vests over four years with 1/48 of the underlying shares vesting monthly starting one month after the grant date.
Ocular Therapeutix Chief Legal Officer Todd Anderman reported new equity awards. On January 2, 2026, he received 64,900 restricted stock units (RSUs), each representing one share of common stock, at a price of $0. These RSUs vest over three years, with one-third vesting on the first anniversary of the grant date and the remaining shares vesting in equal annual installments thereafter, subject to continued service.
On the same date, he was also granted a stock option for 197,650 shares of common stock with an exercise price of $11.82 per share and expiration on January 1, 2036. The option vests over four years, in monthly installments of 1/48 of the total starting one month after the grant date. After these transactions, he beneficially owned 152,468 shares of common stock directly.
Ocular Therapeutix Chief Commercial Officer Steve Lawrence Meyers reported new equity awards. On January 2, 2026, he received 64,900 restricted stock units, each representing one share of common stock, granted at no cash cost. These RSUs vest over three years, with one-third vesting on the first anniversary of the grant date and additional one-third portions vesting at the end of each of the next two years, subject to continued service.
He was also granted a stock option covering 197,650 shares of common stock at an exercise price of $11.82 per share. This option vests over four years in equal monthly installments of 1/48 of the shares beginning one month after the grant date, contingent on continued service. Following these transactions, he beneficially owned 217,628 shares of common stock directly.
Ocular Therapeutix reported new equity awards to its Chief Strategy Officer, Sanjay Nayak. On January 2, 2026, he received 64,900 restricted stock units, each representing one share of common stock, granted at $0 under the company’s 2021 Stock Incentive Plan.
Subject to his continued service, these RSUs vest over three years in three equal annual installments. He was also granted a stock option for 197,650 shares at an exercise price of $11.82 per share, vesting monthly over four years beginning one month after the grant date, also contingent on continued service. Following the RSU grant, he beneficially owned 342,760 shares of common stock directly.
Ocular Therapeutix, Inc. reported that its Chief Development Officer, Peter Kaiser, received new equity awards on January 2, 2026. He was granted 79,112 restricted stock units (RSUs), each representing one share of common stock. These RSUs vest over three years, with one-third vesting on the one-year anniversary of the grant date and the remaining two-thirds vesting in equal annual installments thereafter, subject to his continued service.
On the same date, he was also granted a stock option for 240,932 shares of common stock with an exercise price of $11.82 per share. This option vests over four years, in monthly installments of 1/48 of the total starting one month after the grant date, again contingent on continued service, and expires on January 1, 2036. Following these grants, he beneficially owned 271,918 shares of common stock, which includes 1,373 shares acquired under the company’s employee stock purchase plan on December 31, 2025.
Ocular Therapeutix Chief Medical Officer Nadia Waheed reported new equity awards. On January 2, 2026, she received 79,112 restricted stock units (RSUs), each representing one share of common stock, at a grant price of $0. These RSUs vest over three years, with one-third vesting on the first anniversary of the grant date and the remaining shares vesting in two equal annual installments, subject to her continued service.
On the same date, she was also granted a stock option for 240,932 shares of common stock at an exercise price of $11.82 per share. This option vests over four years, with 1/48 of the underlying shares vesting monthly beginning one month after the grant date, conditioned on continued service. Following the RSU grant, she beneficially owned 326,280 shares of common stock directly, along with the newly granted option covering 240,932 shares.
Ocular Therapeutix is entering a quiet period starting December 20, 2025 as it prepares for database lock of its SOL-1 Phase 3 clinical trial of AXPAXLI (also known as OTX-TKI) for wet age-related macular degeneration. The company states that SOL-1 data remain on track for the first quarter of 2026. Its next planned investor communication is expected in early February 2026, when it plans to release financial results for the fourth quarter and full year 2025 and provide an update on the timing of SOL-1 data.
Ocular Therapeutix, Inc. (OCUL) reported an insider transaction by its Chief Strategy Officer on a Form 4. On 11/24/2025, the officer sold 1,878 shares of common stock in a transaction coded “S,” at a weighted average price of $12.04 per share.
According to the footnotes, the sale was executed under a durable automatic sale instruction adopted on February 21, 2024, to cover tax withholding obligations tied to the vesting of restricted stock units on November 22, 2025, and is described as non-discretionary. After this sale, the officer beneficially owned 277,860 shares of Ocular Therapeutix common stock in direct form.
Ocular Therapeutix (OCUL) Executive Chairman, President and CEO Pravin Dugel reported insider transactions on Form 4. On November 24, 2025, he sold 19,530 shares of common stock at a weighted average price of $12.04 per share under a durable automatic sale instruction adopted on February 21, 2024, to cover tax withholding from restricted stock units vesting on November 22, 2025. These sales were not a discretionary trade.
After this sale, he directly owned 3,157,960 shares. On November 26, 2025, his spouse transferred 49,754 shares for no consideration to the Pravin Dugel 2024 Irrevocable Trust, and the same number of shares was recorded as acquired by the trust. Following this transfer, 300,115 shares were held indirectly through the trust, and the reporting person remained the beneficial owner of those securities.